liraglutide Pen Injector [Saxenda]

Corresponding author: Sungrae Kim Division of Endocrine and Metabolism, The Catholic University of Korea, Bucheon St. Mary’s… Expand

ABSTRACT Obesity is a global epidemic that contributes to a number of health complications including cardiovascular disease, type… Expand

Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as… Expand

Obesity is a significant concern in the United States, affecting approximately 35% of the population. Comorbidities, such as… Expand

 

Liraglutide (Saxenda®; 3 mg dose), a glucagon-like peptide-1 receptor agonist, is indicated as an adjunct to a reduced-calorie… Expand

Despite much advertising to the contrary, there are no dietary supplements that safely and effectively cause weight loss… Expand

Globally, obesity has reached epidemic proportions and poses an ever increasing burden from a societal and healthpayer… Expand

This article highlights important prescribing information for some drugs that received FDA approval within the past year. These… Expand